

MINUTES

<u>Health, Medical and Research Committee Meeting</u> <u>March 18th 2004</u>

Participants:

Pr. Arne Ljungqvist, Chairman and Reporter to HM&R Committee	Connected by phone at the end of meeting
Pr. Christiane Ayotte	Attending
Pr. Eduardo De Rose, acting as Chairman	Attending
Pr. Kenneth Fitch	Attending (Via teleconference)
Pr. Theodore Friedman	Attending
Pr. Carlos Hamilton	Attending
Pr. Luis Horta	Attending
Pr. Ichiro Kono	Attending
Dr. Jean-Claude Mbanya	Attending
Mr. Alexander Popov	Absent
Pr. Bengt Saltin	Attending
Dr. Patrick Schamasch	Attending
Dr. Gary Wadler, acting as Reporter for the List Committee	Attending

WADA staff:

Dr. Alain Garnier, Medical Director Ms. Violet Maziar, Assistant to the Science Director Dr. Olivier Rabin, Science Director Dr. Ann-Muriel Steff, Research Manager

1. <u>Welcome and Introduction</u>

- Eduardo De Rose, acting as chair, welcomed the participants.
- Participants introduced themselves
- The main functions of the HM&R Committee and the status of WADA budget regarding Science were explained by Olivier Rabin.

2. <u>Update Lab Committee</u>

- For the first time, all 31 Laboratories must work under the International Standard for Laboratories;
- Proficiency testing will be held 4 times a year (instead of 1 previously);
- ILAC has been approached to work together with WADA in order to combine accreditation for the International Standard for Laboratories and ISO 17025.

3. <u>Update List Committee</u>

- Gary Wadler updated the members on the major points discussed at the previous List Committee Meeting.
- As a follow-up to questions raised during the List Committee about FSH and LH, Christiane Ayotte, Carlos Hamilton and Jean-Claude Mbanya will gather information on the following issues:
 - Normal values of FSH and LH in urine, with the goal of determining a meaningful threshold for these substances in urine;
 - Methodology currently employed to measure these substances in urine and associated variations in measurement.
- The recent modification on the 2004 List, concerning the definition of analogues and mimetics was explained in details by Olivier Rabin.

4. <u>Update TUE Committee</u>

- The first meeting of the TUE Committee is scheduled for the end of March 2004.
- Up to now, WADA received approximately 500 TUE notifications, with12 full TUEs, the remaining being Abbreviated TUEs.
- A considerable effort is being made in order to organize the TUE process for Athens, in particular for the use of Glucocorticosteroids.
- Reminders to be sent to the Federations to underline the importance of TUEs for Athens.

5. <u>Research projects 2004</u>

- <u>2004 Research Themes.</u>
 - The Committee decided to keep a "general" call for proposals with wide description of research themes rather than indicating areas for which WADA has a specific interest.
 - The "specific" call for proposals will follow the general one if WADA research priorities have not been fulfilled.
 - Scientists, scientific organizations or pharmaceutical companies working in the field of these specific research themes have to be identified and approached by members of the Committee and WADA.
 - The Committee recommends that separate budgets be established for the "general" versus "specific" research projects. An additional "flexible" budget is to be put in place for "emergency" situations such as, but not limited to, the discovery of a new agent or the implementation of a new technique among labs.
 - The Committee recommends that WADA widens its audience (scientific journals, scientific societies websites, etc.) when launching the call for proposals, in order to receive more applications and select the best ones.
 - The "general" research themes for 2004 will be:
 - Compounds and/or methods enhancing oxygen delivery;
 - Compounds and/or methods enhancing growth;
 - Gene and cellular technologies applied to sports;
 - Projects relating to the <u>List of Prohibited Substances</u>.

- "Specific" research themes for 2004, representing research priorities, will be defined by WADA and circulated to HM&R Committee members for discussion.
- Application form
 - Section 13 will be modified in order to include more detailed information on the integration of the research proposal with department/university/national anti-doping programs, on other funding sources and on potential conflicts of interest.

6. <u>Review of the EPO test</u>

- Anti-doping lab scientists expert in urine EPO detection have drafted a Technical Document on the test, to be circulated to all accredited labs in the near future.
- In order to more closely follow and coordinate ongoing research on EPO, it is proposed that a task force led by Bengt Saltin be created.
- Other members of the HM&R Committee to partake to this task force will be determined by Bengt Saltin and Arne Ljungqvist.

7. <u>Hypoxic chambers</u>

- Alain Garnier presents the results of a French study on hypoxic training.
- Olivier Rabin underlines the necessity of a clear statement from WADA on the use of such devices, based on the 3 criteria of the World Anti-Doping Code.
- A thorough evaluation of whether or not hypoxic chambers fulfill the Code criteria defining "prohibited substances" will be undertaken. Bengt Saltin will prepare a position paper summarizing the different studies performed on hypoxic chambers.
- Based on the position paper, the issue will be readdressed by HM&R Committee members.

8. <u>Content of the athlete's passport.</u>

- Medical data useful in an athlete's passport have been identified and include, without being limited to: Hemoglobin concentration, Percent reticulocytes, Hematocrit, T/E ratio, Testosterone concentration corrected for specific gravity, EPO isoform profiles.
- There is however a shared concern by some members of the Committee on the feasibility of gathering and making such medical information available, for privacy reasons.

9. <u>Confidentiality issues.</u>

• Christiane Ayotte informed the Committee of her wish to have part of the Confidentiality Agreement re-worded before signing. The issue has been transferred to WADA Legal Department.

10. Any other business.

• The next HM&R meeting will be held on September 10th, 2004.